Session » (0886–0898) SLE – Animal Models Poster

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 0886

Neonatal Roseolovirus Infection Predisposes to Development of Lupus-like Disease After TLR7 Stimulation

Abstract Number: 0887

Dapagliflozin Modulates Inflammation and Germinal Centers in Lupus by Increasing Regulatory T Cells

Abstract Number: 0888

Functionally Selective Immunomodulator Shows Robust Efficacy in Spontaneous Lupus Mouse Model

Abstract Number: 0889

Axl Receptor Tyrosine Kinase Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice by Regulating Macrophage Polarization

Abstract Number: 0890

Specificity of Brain-Intrinsic and Hematopoietic-Derived Mechanisms in Mediating Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

Abstract Number: 0891

Selective and Potent Inhibition of Cyclic GMP-AMP Synthase (cGAS) Fully Normalizes Autoinflammation Across Tissues in a Trex1-/- Mouse Model for Type I Interferonopathies

Abstract Number: 0892

Single-Cell RNA Sequencing Reveals Keratinocytes and Fibroblasts Drive Hippo and TGFb Dysregulation and Fibrosis in Epidermal Overexpression of VGLL3 in Cutaneous Lupus

Abstract Number: 0893

Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model

Abstract Number: 0894

The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light

Abstract Number: 0895

Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus

Abstract Number: 0896

Targeting Toll-Like Receptor 7 with DS-7011a, a Promising Novel Antagonistic Antibody for the Treatment of Systemic Lupus Erythematosus

Abstract Number: 0897

Steroid-sparing Effects of Afimetoran (BMS-986256), an Equipotent Toll-like Receptor (TLR)7 and TLR8 Antagonist, in a Lupus Mouse Model

Abstract Number: 0898

The Role of the Endothelin System in the Development of TLR7-accelerated Lupus-Associated Cardiac Dysfunction

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.